APM Stock Summary and Trading Ideas (Aptorum Group Limited - Class A | NASDAQ:APM)

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Aptorum Group Limited - Class A trades on the NASDAQ stock market under the symbol APM.

As of May 22, 2026, APM stock price climbed to $0.85 with 4,922 million shares trading.

APM has a beta of 1.57, meaning it tends to be more sensitive to market movements. APM has a correlation of 0.03 to the broad based SPY ETF.

APM has a market cap of $6.92 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APM traded as high as $17.49 and as low as $.46.

APM has underperformed the market in the last year with a return of -1.2%, while the SPY ETF gained +29.1%. In the last 3 month period, APM fell short of the market, returning +7.5%, while SPY returned +8.4%. However, in the most recent 2 weeks APM has outperformed the stock market by returning +1.2%, while SPY returned +1.1%.

APM support price is $.79 and resistance is $.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APM shares will trade within this expected range on the day.